Efficacy of Postnatal In Vivo Nonsense Suppression Therapy in a Pax6 Mouse Model of Aniridia
Nonsense mutations leading to premature stop codons are common occurring in approximately 12% of all human genetic diseases. Thus, pharmacological nonsense mutation suppression strategies would be beneficial to a large number of patients if the drugs could be targeted to the affected tissues at the...
Saved in:
Main Authors: | Xia Wang (Author), Kevin Gregory-Evans (Author), Kishor M. Wasan (Author), Olena Sivak (Author), Xianghong Shan (Author), Cheryl Y. Gregory-Evans (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2017-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Restoration of functional PAX6 in aniridia patient iPSC-derived ocular tissue models using repurposed nonsense suppression drugs
by: Dulce Lima Cunha, et al.
Published: (2023) -
Protecting Pax6 3' UTR from MicroRNA-7 Partially Restores PAX6 in Islets from an Aniridia Mouse Model
by: Kevin Yongblah, et al.
Published: (2018) -
A nonsense mutation in a family with congenital aniridia
by: Kyoung Hee Han, et al.
Published: (2016) -
PAX6 gene variations associated with aniridia in south India
by: Shashikant Shetty, et al.
Published: (2004) -
Psychoneurological Disorders in Children with Congenital Aniridia and <i>PAX6</i>-Associated Syndromes
by: Olga S. Kupriyanova, et al.
Published: (2023)